RxDoctor Payments Data

Russ Levitan, MD

Anesthesiology · San Luis Obispo, CANPI 1992783302

Payments from drug & device makers

$4,716in general payments, 2019–2025

Across 136 payments — averaging $34.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Tersera Therapeutics LLC$719
  • AbbVie$698
  • Abbott$356
  • Boston Scientific$177
  • Vertex$100
  • plus $596 from 19 others

What the payments were for

  • Food & beverage$4,35992%
  • Education$3578%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,716 in reported general payments places this provider in the 95th percentile of 5,717 anesthesiology providers in California.

See all anesthesiology providers in California

Medicare billing

Part B allowed, 2024
$507,477
Medicare patients
257
Services billed
4,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant11$63,987
NucyntaTapentadol Hcl13$32,771
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen670$27,048
OxycontinOxycodone Hcl38$24,203
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen364$16,957
BelbucaBuprenorphine Hcl12$12,173
Oxycodone Hcl338$9,715
Gabapentin376$9,257
Morphine Sulfate ErMorphine Sulfate181$9,136
Hydromorphone Hcl302$8,552
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl26$8,528
Emgality SyringeGalcanezumab-Gnlm12$8,273
Fentanyl74$5,936
Lidocaine55$5,287
Morphine Sulfate124$5,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$698$63,98711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,717 anesthesiology providers in California.

Other anesthesiology in San Luis Obispo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →